Experimental targeted therapy shows early promise against medulloblastomas (video)



Researchers from St. Jude Children’s Research Hospital and the Pediatric Brain Tumor Consortium (PBTC) presented today at the American Society of Clinical Oncology the findings of a pediatric brain tumor study using an experimental drug that targets the underlying genetic makeup of the tumor. The research focused on a new way to attack the tumors by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas.